PET/CT imaging 2 h after injection of [18F]PSMA-1007 can lead to higher staging of prostate cancer than imaging after 1 h

EJNMMI Reports

Table 2 Findings by individual readers

	Any metastases found		Change in number of found metastases
	At 1 h	At 2 h	More at 1 h	More at 2 h	p^c
Pelvic LNs n (%)	110 (18.8%)	130 (22.2%)	7 (1.2%)	51 (8.7%)	< 0.001*
Abdominal LNs	23 (3.9%)	29 (5.0%)	1 (0.2%)	10 (1.7%)	0.008
Supradiafragmal LNs	19 (3.2%)	20 (3.4%)	0	5 (0.9%)	0.039
Inguinal LNs	7 (1.2%)	11 (1.8%)	0	5 (0.9%)	0.039
Bone	66 (11.3%)	84 (14.4%)	10 (1.7%)	30 (5.1%)	0.003*

	Status of prostate/prostate bed
	At 1 h	At 2 h	Only at 1 h	Only at 2 h	p^d
Primary tumor detected^a	342 (89.1%)	354 (92.2%)	7 (1.8%)	19 (4.9%)	0.031
SV involvement suspected^a	67 (17.4%)	83 (21.6%)	4 (1.0%)	20 (5.2%)	0.002*
Local recurrence suspected^b	48 (23.9%)	56 (27.9%)	1 (0.5%)	9 (4.5%)	0.021

n = 585 (3 readings of 195 patients). n indicates number of readings, not number of suspected metastases
^aPrimary staging only (n = 3 × 128 = 384)
^bBCR only (n = 3 × 67 = 201)
^cUsing Wilcoxon signed rank test to test for difference in number of found metastases at 1 and 2 h
^dUsing McNemar’s test to test for difference in status/stage at 1 and 2 h
*p < 0.005